Dear Behailu

I may suggest the following, and you can also see the attached article for more details. check the references in the article to get more ideas. good luck

Management of cancer pain. Pharmacology and principles of management

Morphine and alternative opioids in cancer pain: the EAPC recommendations

Dear Behailu

I may suggest the following, and you can also see the attached article for more details. check the references in the article to get more ideas. good luck

Management of cancer pain. Pharmacology and principles of management

Morphine and alternative opioids in cancer pain: the EAPC recommendations

Hi Behailu,

During the last decade we’ve developed Xenobiotical Virology, an interdisciplinary biomedical discipline dealing with mechanisms of potent xenobiotics’ effect on dioxin response element (DRE)-containing genes of human viruses, and transcription factors and cytokines linked to malignancy pathways. By using in cilico (SITECON tool) and experimental data, several known cancer-associated human viruses were shown to possess multiple potentially active DREs in their promoters, namely, in Epstein-Barr virus promoters, L1A and L1, each contains 16 DRE, and gene of EBV R1 145K has 11 DRE. Also, genes encoding some major proteins of herpes simplex virus (HSV) type 1 have from 7 to 8 promoter DRE. Also, in addition to viral genes, human genes encoding major “proviral” chemokine RANTES/CCL5, and transcription factors NF-κB3/p65/RelA and STAT3, all possess 7 to 9 active 5’ upstream DRE, which makes these genes more susceptible to TCDD-AhR-Arnt transcriptional complex. So, Behailu, while choosing among the most prospective research topics on oncology pharmacotherapy, would you mind to assess the above  mechanistic data, and consider searching newly anticancer drugs among inhibitors of human virally-driven malignancies, which are antagonists ligands of cytosolic Ah receptor of infected host cells, or act as strong modifiers of AhR-Arnt transcriptional complex binding to viral DRE.

Best wishes,

Ilya

how about creating a project that would use computer and AI empowered technology to select appropriate targets in oncology? The basic premise would be - there are hundreds of thousands of new drugs, but we are trying each one on thousands of patients at the time spending millions on clinical trials. Could we not start selecting patients with appropriate targets ? By selecting the appropriate patient population, give them the right drug(s), we may succeed much faster.  

-          Personalized medicine – the identification of right cancer targets, development of right agents to attack them, the selection of right patients;

-          Immunotherapy – to help the immune system to deal with cancer;

-          To find and apply efficient new strategies to overcome the (multi)drug resistance of cancer cells, to improve the ways to predict the drug sensitivity/resistance of the patient to the planned treatment;

-          To decrease the side effects of anticancer therapy by “turning it” into selective targeted anticancer therapy (Whan about nanooncology, adequate drug delivery systems, nanotheranostics?);

-          To decrease cancer pain…

Good luck!

Currently the hottest topic is immunotherapy for cancer. You can select any tumor type of choice (probably one that is not studied by other groups to much) and look if there is a immune-response and if this can be increased by interference with the T-cell immune checkpoint pathways (CTLA-4 or PD-1)

look here an anywhere else  https://en.wikipedia.org/wiki/CTLA-4

and https://en.wikipedia.org/wiki/Programmed_cell_death_protein_1

There are several established and experimental drugs that target this mechanism, and it should be easy to set up a pharmacological research project on this.

regards,  Michael

thanks all of you for your comment. I have applied the scholarship by taking and modifying 2 topics from your comment!!!!!

Cannabis for chemo-therapy-induced nausea.